Search - tctmd.com

Displaying 261 - 268 of 268

Sort: Relevancy | Date

News Daily News

Muchos Pacientes con Insuficiencia Cardíaca Mejoran su Calidad de Vida Post-TAVR a pesar de la Alta Mortalidad descrita

January 12, 2015

Presentation

Clinical Outcomes and Surrogate Efficacy Data for a Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients with Ischemic or Nonischemic Chronic Heart Failure

Presenter: Emerson C. Perin

January 27, 2013

News Conference News Cell Therapy 2013

Small Heart Failure Studies Show Positive Trends for Cell Therapy

January 27, 2013

Presentation Cell Therapy 2013

Clinical Outcomes and Surrogate Efficacy Data for a Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells (Revascor™) in Patients With Chronic Heart Failure of Ischemic or Nonischem

Presenter: Kenneth M. Borow

January 22, 2013

Presentation Cell Therapy 2013

Clinical Outcomes and Surrogate Efficacy Data for a Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells

Presenter: Kenneth Borow

January 22, 2013

Presentation TCT 2012

Atrial Fibrillation:
1. CHADS2 vs. CHA2DS2-VASc Risk Assessment.
2. AHA/ACC vs. ACCP/ESC Approach to Stroke Prevention.

Presenter: Peter Brady

October 23, 2012

News Conference News ESC 2012

Renal Denervation Shows Promise for Heart Failure, Ongoing Success Against Hypertension

August 29, 2012

News Conference News ESC 2012

Good Outlook for Heart Failure Patients Given Ventricular Restoration Device

Yael L. Maxwell

August 29, 2012

Advertisement

Muchos Pacientes con Insuficiencia Cardíaca Mejoran su Calidad de Vida Post-TAVR a pesar de la Alta Mortalidad descrita

Clinical Outcomes and Surrogate Efficacy Data for a Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients with Ischemic or Nonischemic Chronic Heart Failure

Small Heart Failure Studies Show Positive Trends for Cell Therapy

Clinical Outcomes and Surrogate Efficacy Data for a Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells (Revascor™) in Patients With Chronic Heart Failure of Ischemic or Nonischem

Clinical Outcomes and Surrogate Efficacy Data for a Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells

Atrial Fibrillation:
1. CHADS2 vs. CHA2DS2-VASc Risk Assessment.
2. AHA/ACC vs. ACCP/ESC Approach to Stroke Prevention.

Renal Denervation Shows Promise for Heart Failure, Ongoing Success Against Hypertension

Good Outlook for Heart Failure Patients Given Ventricular Restoration Device

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content